Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S458000
Reexamination Certificate
active
07863324
ABSTRACT:
The present invention provides methods for inhibiting the growth of androgen-independent prostate cancer tumor cells in a human comprising administering to the human. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived compounds useful in the alleviation of cancer.
REFERENCES:
patent: 3995060 (1976-11-01), Neri et al.
patent: 4474813 (1984-10-01), Neri et al.
patent: 4636505 (1987-01-01), Tucker
patent: 4897256 (1990-01-01), Adjei et al.
patent: 5023088 (1991-06-01), Wong et al.
patent: 5510460 (1996-04-01), Hayward
Sausville et al. Cancer Research, 2006, vol. 66, pp. 3351-3354.
Johnson et al. British J. of Cancer, 2001, 84(10):1424-1431.
Singh et al. Endocrine-Related Cancer, 2006, vol. 13, pp. 751-778.
Lamb et al., Androgen receptors and their biology. Vit. Horm., 62: 199-229, 2001.
Wilding, The importance of steroid hormones in prostate cancer. Cancer Surv., 14: 113-130, 1992.
Wilding, Endocrine control of prostate cancer. Cancer Surv., 23: 43-62, 1995.
Jemal et al., Cancer Statistics, 2003. CA Cancer J. Clin., 53: 5-26, 2003.
Gronberg, Prostate cancer epidemiology. Lancet, 361: 859-864, 2003.
Evans et al., On the existence of a hitherto unrecognized dietary factor essential for reproduction. Science, 56: 650-651, 1922.
Brigelius-Flohe et al., Vitamin E: function and metabolism. FASEB J., 13: 1145-1155, 1999.
Burton et al., Vitamin E: antioxidant activity, biokinetics, and bioavailability. Annu. Rev. Nutr., 10: 357-382, 1990.
Horoszewicz, et al., LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
Ripple et al., Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J. Natl. Cancer Inst., 89: 40-48, 1997.
Riegman et al., The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol., 5: 1921-1930, 1991.
Young et al., Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res., 51: 3748-3752, 1991.
Warriar et al., Anti-androgens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP. Prostate, 24: 176-186, 1994.
Veldscholte et al., Studies on the human prostatic cancer cell line LNCaP. J. Steroid Biochem. Mol. Biol., 49: 341-346, 1994.
Klein et al., Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat. Med., 3: 402-408, 1997.
Israel et al., RRR-•-tocopherolsuccinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Nutr. Cancer, 24: 161-169, 1995.
Venkateswaran et al., Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J. Urol., 168: 1578-1582, 2002.
Ni et al., Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem. Biophys. Res. Commun., 300: 357-363, 2003.
Gunawardena et al., Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis. Prostate, 44: 287-295, 2000.
Israel et al., Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. Nutr. Cancer, 36: 90-100, 2000.
Zhang et al., Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc. Natl. Acad. Sci. U.S.A., 99: 7408-7413, 2002.
Wilding et al., Aberrant response in vitro of hormone-responsive prostate cells to anti-androgens. Prostate, 14: 103-115, 1989.
Rago et al., DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Anal. Biochem., 191: 31-34, 1990.
Thompson et al., Transient promoter activity in primary rat mammary epithelial cells evaluated using particle bombardment gene transfer. In Vitro Cell. Dev. Biol. 29A: 165-170, 1992.
Veldscholte et al.,A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun., 173: 534-540, 1990.
Lieberman, Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development. Urol., 58 (S2A): 83-90, 2001.
Nakamura et al., Curcumin down-regulates AR gene expression and activation in prostate cancer cells. Int. J. Oncol., 21: 825-830, 2002.
Le et al., Plant-derived 3, 3•-diindolylmethaneis a strong androgen antagonist in human prostrate cancer cells. J. Biol. Chem., 278: 21136-21145, 2003.
Burton et al., Vitamin E as an antioxidant in vitro and in vivo. In: Biology of Vitamin E: Chiba Foundation Symposium 101, pp. 4-18. London: Pitman, 1983.
Dimitrov et al., Plasma tocopherol concentrations in response to supplemental vitamin E. Am. J. Clin. Nutr., 53: 723-729, 1991.
Traber et al., Synthetic as compared with natural vitamin E is preferentially excreted as •CEHOn human urine: studies using deuterated alpha-tocopheryl acetates. FEBS Lett., 437: 145-148, 1998.
Thompson Todd A.
Wilding George
Anderson James D
Quarles & Brady LLP
Wisconsin Alumni Research Foundation
LandOfFree
Chroman-derived compounds for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chroman-derived compounds for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chroman-derived compounds for the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2705284